Leading animal healthcare company, Hester Biosciences reported a standalone net profit of Rs 12.24 crore for the quarter ended June 2021 as against a net profit of Rs 7.62 crore in the corresponding period last year – growth of 60 per cent. Revenue from operations for the Q1FY22 was reported at Rs 58.51 crore, a growth of 50 per cent as compared to revenue of Rs 38.88 crore in the corresponding period last year. EPS for Q1FY22 was reported at Rs 14.38 per share.

The company achieved an improved operational and financial performance in Q1 FY22 as compared to the corresponding quarter of FY21. The EBITDA margin was reported at 31.02 per cent and the net profit margin at 20.92 per cent in Q1FY22. The market and economic recovery has supported well for the growth of the poultry and animal industry and is expected to continue in the coming period. The company is constantly investing in the geographical market expansion and marketing manpower to achieve the budgeted topline.

During Q1 FY22, the overall topline grew by 50 per cent, compared to Q1FY21 which was affected by a nationwide lockdown during the initial period of the pandemic. Overall, the sales of vaccines have registered a growth of 41 per cent in Q1 FY22, and the sale of Health Products have registered a growth of 94 per cent in Q1 FY22. Domestic sales have registered a growth of 61 per cent in Q1 FY22. The opening up of the domestic market has resulted in a higher demand for the products.        Export sales have registered a marginal de-growth of 8 per cent in Q1 FY22. Export orders are affected due to restricted cargo movements globally.